Even Mild Increase in Pulmonary Arterial Pressure Following Kidney Transplantation is Associated with Increased Mortality
Abstract Body (Do not enter title and authors here): Background In end-stage renal disease (ESRD), elevated systolic pulmonary artery pressure (sPAP) is common, attributed to post-capillary pulmonary hypertension (PH) and associated with adverse outcomes. Kidney transplantation (KT) may mitigate ESRD-PH. We aimed to profile sPAP trajectory in a national cohort of ESRD patients pre- and post-KT, and link findings to clinical outcome. Methods We analyzed retrospectively all patients within the Veterans Affairs Healthcare System undergoing KT between 2000-2019 with sPAP recorded pre- and post-KT by echocardiography. PH was defined by >35mmHg. Patients were assigned to one of the following groups: Never PH, New PH post-KT, Resolved PH post-KT, and Persistent PH. Spline curve and Kaplan-Meier analyses were used to test the association of sPAP or PH group with all-cause mortality, adjusted for age and sex. Results From 631 patients (median 62 [IQR 58-65]yr; 97% male), there were 231 (36.6%), 184 (29.2%), 133 (21.1%), and 83 (13.1%) patients in the Persistent PH, Never PH, Resolved PH, and New PH groups, respectively. Never PH, Resolved PH and New PH had, overall, similar cardiopulmonary comorbidities (Tab. 1). By contrast, Persistent PH had the highest rate of congestive heart failure, atrial fibrillation, and impaired diastolic relaxation assessed by E/E’. Creatinine post-KT, indicative for graft function, was stable in Never PH, Resolved PH and Persistent PH, but significantly increased in New PH. Of all groups, Resolved PH was associated with the most favorable survival rate (HR 0.73 [95%CI 0.51-1.05], p=0.087). New PH and Persistent PH were associated with a 51% (HR=1.51 [95%CI 1.06-2.15], p=0.023) and 37% (HR=1.37 [95%CI 1.03-1.82], p=0.029; referent group for all: Never PH) increase in adjusted mortality risk post-KT (Fig. 1a). Overall, we observed 21% (HR=1.21 [95%CI 1.11-1.31], p<0.001) increase in mortality hazard adjusted for age, sex and baseline sPAP, per 10mmHg increment increase in sPAP from pre-KT to post-KT whereas a 10mmHg sPAP decrease was associated a 17% decrease in mortality (HR=0.83 [95%CI 0.76-0.90], p<0.001) (Fig. 1b). Conclusion These data suggest that PH is common post-KT and includes a sizeable group of patients without PH pre-KT. Increased PAP or failure for PH to resolve post-KT were independently associated with mortality. Overall, these data warrant prospective studies in sex-balanced cohorts that use PH to stratify KT candidacy and PAP as a longitudinal biomarker of graft function post-KT.
Zeder, Katarina
( University of Maryland
, Bethesda
, Maryland
, United States
)
Kundu, Suman
( Vanderbilt University Medical Center
, Nashville
, Tennessee
, United States
)
Siew, Edward
( Vanderbilt University for Kidney Disease and Integrated Program for Acute Kidney Injury
, Nashville
, Tennessee
, United States
)
Birdwell, Kelly
( Vanderbilt University for Kidney Disease and Integrated Program for Acute Kidney Injury
, Nashville
, Tennessee
, United States
)
Freiberg, Matthew
( Vanderbilt University Medical Center
, Nashville
, Tennessee
, United States
)
Kovacs, Gabor
( Medical University of Graz
, Graz
, Austria
)
Brittain, Evan
( Vanderbilt University Medical Center
, Nashville
, Tennessee
, United States
)
Maron, Brad
( University of Maryland
, Bethesda
, Maryland
, United States
)
Author Disclosures:
Katarina Zeder:DO NOT have relevant financial relationships
| Suman Kundu:DO NOT have relevant financial relationships
| edward siew:DO have relevant financial relationships
;
Other (please indicate in the box next to the company name):American Society of Nephrology:Past (completed)
; Royalties/Patent Beneficiary:UptoDate:Active (exists now)
; Consultant:Novartis:Active (exists now)
| Kelly Birdwell:DO NOT have relevant financial relationships
| Matthew Freiberg:No Answer
| Gabor Kovacs:No Answer
| Evan Brittain:DO NOT have relevant financial relationships
| Brad Maron:DO have relevant financial relationships
;
Consultant:Actelion:Active (exists now)
; Research Funding (PI or named investigator):Deerfield Company:Active (exists now)